For instance, a novel type of antibody, named YM101, was developed to enhance the effect of ICIs by blocking PD-1/PD-L1 and TGF-β simultaneously, which was found to have a superior anti-tumor effect compared to the monotherapies (53). This evidence concerns the gene TGFB1 and neoplasm.